Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Bafna Pharmaceuticals IPO is a fixed price issue of ₹25.60 crores. The issue is entirely a fresh issue of 0.64 crore shares of ₹25.60 crore.
Bafna Pharmaceuticals IPO bidding started from May 27, 2008 and ended on May 30, 2008. The shares got listed on BSE on Jun 27, 2008.
Bafna Pharmaceuticals IPO price is ₹40.00 per share .
Keynote Financial Services Ltd. is the book running lead manager and Cameo Corporate Services Ltd. is the registrar of the issue.
Refer to Bafna Pharmaceuticals IPO RHP for detailed Information.
| IPO Date | May 27, 2008 to May 30, 2008 |
| Listing Date | June 27, 2008 |
| Face Value | ₹10 per share |
| Issue Price Band | |
| Issue Price Final | ₹40 per share |
| Lot Size | |
| Sale Type | Fresh Capital |
| Total Issue Size | 64,00,206 shares (aggregating up to ₹25.60 Cr) |
| Issue Type | Fixed Price IPO |
| Listing At | BSE |
| Share Holding Pre Issue | 95,81,129 shares |
| Share Holding Post Issue | 1,59,81,129 shares |
Bafna Pharmaceuticals IPO offers total 64,00,000 shares. Out of which 32,00,000 (50.00%) allocated to NII, 32,00,000 (50.00%) allocated to RII.
| Investor Category | Shares Offered |
|---|---|
| NII (HNI) Shares Offered | 32,00,000 (50.00%) |
| Retail Shares Offered | 32,00,000 (50.00%) |
| Total Shares Offered | 64,00,000 (100.00%) |
Bafna Pharmaceuticals IPO opens on May 27, 2008, and closes on May 30, 2008.
| IPO Open Date | Tue, May 27, 2008 |
| IPO Close Date | Fri, May 30, 2008 |
| Tentative Listing Date | Fri, Jun 27, 2008 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, May 30, 2008 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 1995, Bafna Pharmaceuticals Limited is engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The Company manufactures 126 formulations under various therapeutic segments, such as anti-infective, cholesterol lowering agents, analgesic and antipyretic, antihelmintics, appetite stimulants, cough and cold preparations, antiulcerants anti diabetic, and vitamins.
In 2006, Bafna has set up an 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. The unit has been WHO GMP certified and also ISO 9000 certified. The products manufactured in this factory caters to the markets of Srilanka, Ghana and Ukraine. Bafna was involved in the execution of contracts for the generic division of M/s. Croslands from the period 1994 to 2001. Bafna was awarded the WHO GMP certification during the year 1995. Presently around 57 products of the company are registered in Srilanka, 4 products in Ukraine, 1 product in Ghana. The company received the Best Supplier award from the Srilankan Government during 2005.
| Particulars | For the year/period ended (Rs. in lacs) | ||||
| 30-Jun-07 | 31-Mar-07 | 31-Mar-06 | 31-Mar-05 | 31-Mar-04 | |
| Total Income | 432.02 | 3861.96 | 2136.47 | 2662.65 | 1521.33 |
| Profit After Tax (PAT) | 49.70 | 104.23 | 92.27 | 89.81 | 44.51 |
| KPI | Values |
|---|---|
| RoNW | 10.65% |
The Company Bafna Pharmaceuticals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (in Millions) |
|---|---|---|
| 1 | Brand building in domestic markets | 104.40 |
| 2 | Registration of Company, products andBrand building in International Markets | 30.30 |
| 3 | MHRA Accrediation | 10.80 |
| 4 | Setting up R&D facilities | 30.00 |
| 5 | Working Capital Requiremen | 20.00 |
| 6 | Part repayment ofloan from SBI | 40.00 |
| 7 | Public Issue Expenses | 20.50 |
| Listing Date | June 27, 2008 |
| BSE Script Code | 532989 |
| NSE Symbol | BAFNAPHARM |
| ISIN | INE878I01014 |
| Final Issue Price | ₹40 per share |
| BSE Listing Group | B |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹40.00 |
| Open | ₹43.80 |
| Low | ₹37.30 |
| High | ₹47.20 |
| Last Trade | ₹38.50 |
Bafna Pharmaceuticals Ltd.
Bafna Pharmaceuticals Limited,
299
Thambu Chetty Street,
Chennai, Tamil Nadu, 600001
Phone: + 91-44-25267517
Email: cs@bafnapharma.com
Website: http://www.bafnapharma.com
Cameo Corporate Services Ltd.
Phone: +91-44-28460390
Email: cameo@cameoindia.com
Website: https://ipo.cameoindia.com/
Bafna Pharmaceuticals IPO is a main-board IPO of 64,00,206 equity shares of the face value of ₹10 aggregating up to ₹25.60 Crores. The issue is priced at ₹40 per share. The minimum order quantity is .
The IPO opens on May 27, 2008, and closes on May 30, 2008.
Cameo Corporate Services Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE.
Zerodha customers can apply online in Bafna Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Bafna Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Bafna Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Bafna Pharmaceuticals IPO opens on May 27, 2008 and closes on May 30, 2008.
Bafna Pharmaceuticals IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Bafna Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Bafna Pharmaceuticals IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Bafna Pharmaceuticals IPO allotment status.
The Bafna Pharmaceuticals IPO listing date is on Friday, June 27, 2008.
Useful Articles
RHP